HICKY, Inc., a start-up company that originated from Tokyo Biodesign, is developing a novel minimally invasive medical device for central sleep apnea”.

Marked central sleep apnea (CSA) is observed in patients with heart failure. It increases re-hospitalization rates and worsens prognosis in such patients.

We are developing a minimally invasive medical device for the management of CSA aiming at combining endovascular treatment with wireless power transmission to offer a better quality of sleep and quality of life besides improving the overall prognosis in patients with heart failure.